Follow
Kalliopi Zachou
Kalliopi Zachou
Associate Professor in Medicine, University of Thessaly, Faculty of Medicine
Verified email at med.uth.gr
Title
Cited by
Cited by
Year
Peginterferon plus adefovir versus either drug alone for hepatitis delta
H Wedemeyer, C Yurdaydìn, GN Dalekos, A Erhardt, Y Çakaloğlu, ...
New England Journal of Medicine 364 (4), 322-331, 2011
5512011
Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta
B Heidrich, C Yurdaydın, G Kabacam, BA Ratsch, K Zachou, B Bremer, ...
Hepatology 60 (1), 87-97, 2014
3262014
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience
HL Tillmann, J Hadem, L Leifeld, K Zachou, A Canbay, C Eisenbach, ...
Journal of viral hepatitis 13 (4), 256-263, 2006
3232006
Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics
NK Gatselis, K Zachou, GK Koukoulis, GN Dalekos
World journal of gastroenterology: WJG 21 (1), 60, 2015
2742015
autoimmune hepatitis–current management and challenges
K Zachou, P Muratori, GK Koukoulis, A Granito, N Gatselis, A Fabbri, ...
Alimentary pharmacology & therapeutics 38 (8), 887-913, 2013
2422013
Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of …
K Zachou, N Gatselis, G Papadamou, EI Rigopoulou, GN Dalekos
Journal of hepatology 55 (3), 636-646, 2011
2252011
Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease
K Zachou, E Rigopoulou, GN Dalekos
Journal of autoimmune diseases 1, 1-17, 2004
2132004
Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis
EI Rigopoulou, ET Davies, A Pares, K Zachou, C Liaskos, DP Bogdanos, ...
Gut 54 (4), 528-532, 2005
1642005
Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview
GN Dalekos, K Zachou, C Liaskos, N Gatselis
European journal of internal medicine 13 (5), 293-303, 2002
1642002
Quantitative HBsAg and HDV‐RNA levels in chronic delta hepatitis
K Zachou, C Yurdaydin, U Drebber, GN Dalekos, A Erhardt, Y Cakaloglu, ...
Liver International 30 (3), 430-437, 2010
1422010
A real‐world study focused on the long‐term efficacy of mycophenolate mofetil as first‐line treatment of autoimmune hepatitis
K Zachou, NK Gatselis, P Arvaniti, S Gabeta, EI Rigopoulou, ...
Alimentary pharmacology & therapeutics 43 (10), 1035-1047, 2016
1172016
Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?
HL Tillmann, K Zachou, GN Dalekos
Liver International 32 (4), 544-553, 2012
1052012
Clinical and virological heterogeneity of hepatitis delta in different regions world‐wide: the Hepatitis Delta International Network (HDIN)
A Wranke, LM Pinheiro Borzacov, R Parana, C Lobato, S Hamid, ...
Liver International 38 (5), 842-850, 2018
1042018
Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity
KG Oikonomou, K Zachou, GN Dalekos
Autoimmunity reviews 10 (7), 389-396, 2011
1012011
Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score?
NK Gatselis, K Zachou, P Papamichalis, GK Koukoulis, S Gabeta, ...
Digestive and liver disease 42 (11), 807-812, 2010
1002010
Anti‐cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2‐glycoprotein I cofactor or features of antiphospholipid syndrome
K Zachou, C Liaskos, DK Christodoulou, M Kardasi, G Papadamou, ...
European journal of clinical investigation 33 (2), 161-168, 2003
972003
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group
S Pape, RJ Snijders, TJG Gevers, O Chazouilleres, GN Dalekos, ...
Journal of hepatology 76 (4), 841-849, 2022
932022
DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B
GV Papatheodoridis, EI Rigopoulou, M Papatheodoridi, K Zachou, ...
Antiviral Therapy 23 (8), 677-685, 2018
882018
The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other …
PA Papamichalis, K Zachou, GK Koukoulis, A Veloni, EG Karacosta, ...
Journal of autoimmune diseases 4, 1-12, 2007
862007
Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease
NK Gatselis, K Zachou, GL Norman, S Gabeta, P Papamichalis, ...
Autoimmunity 46 (7), 471-479, 2013
822013
The system can't perform the operation now. Try again later.
Articles 1–20